Mardi Dier sold $2.4M of MDGL
EVP and CFO at MADRIGAL PHARMACEUTICALS, INC.. 4,173 shares at an average of $578.34, traded Dec 2, 2025, filed Dec 3, 2025.
Score components
- +22RoleCFO
- +25Trade size$2.4M at market
- +10Share of holdings soldSold 29% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +2.4%, 3m -25.0%, 6m -15.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-055164, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 2, 2025 | MOption exercise Common Stock10b5-1 | +4,173 | $251.63 | $1.1M | 14,613 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -320 | $570.39 | $183k | 14,293 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -410 | $571.99 | $235k | 13,883 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -354 | $573.02 | $203k | 13,529 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -717 | $574.00 | $412k | 12,812 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -120 | $574.95 | $69k | 12,692 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -240 | $576.15 | $138k | 12,452 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -320 | $577.81 | $185k | 12,132 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -258 | $578.83 | $149k | 11,874 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -480 | $579.85 | $278k | 11,394 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -240 | $585.44 | $141k | 11,154 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -240 | $587.85 | $141k | 10,914 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -160 | $589.65 | $94k | 10,754 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -160 | $590.37 | $94k | 10,594 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -74 | $595.20 | $44k | 10,520 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -80 | $596.19 | $48k | 10,440 | Dec 3, 2025 |
| Dec 2, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,173 | $0.00 | $0 | 9,180 | Dec 3, 2025 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 30Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $342k 664 shares | -5% | |
| 35Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $1.4M 2,500 shares | -1% | |
| 21Weak | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $517k 1,042 shares | -9% | |
| 33Weak | MADRIGAL PHARMACEUTICALS, INC. | Richard S Levy director | $2.9M 5,682 shares | -21% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $435k 844 shares | -7% | |
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $854k 1,982 shares | -14% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $181k 419 shares | -3% | |
| 41Moderate | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $155k 360 shares | -3% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub Pres., R&D, and CMO | $212k 491 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.